Li Miaoqing, Wang Xiaoxia, Guo Jia, Qu Junchen, Cao Yu, Song Qingkun, Lu Jun
Department of Medical Oncology, Laboratory for Clinical Medicine, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Department of Clinical Epidemiology Research, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Cancer Med. 2025 Apr;14(7):e70794. doi: 10.1002/cam4.70794.
Digestive system malignancies are a major global health burden, and the role of fatty acid binding protein 5 (FABP5) in these tumors remains controversial.
This meta-analysis aimed to evaluate the correlation between FABP5 expression and clinicopathological features, as well as survival outcomes in digestive system malignancies.
Data from 11 studies (1207 patients) retrieved from PubMed, Embase, Cochrane Library, CNKI, and WanFang were analyzed.
FABP5 overexpression was associated with poorer overall survival (OS), larger tumor size, advanced UICC stage, and increased risk of vascular invasion and lymph node metastasis. Notably, FABP5 overexpression is particularly associated with poorer OS in the subgroup of digestive tract malignancies and larger tumor sizes in the subgroup of Chinese patients.
Cellular experiments demonstrated that FABP5 overexpression enhances proliferation, migration, and invasion in hepatocellular carcinoma (Huh7) and gastric cancer (HGC-27) cell lines, while FABP5 knockdown reduces these effects. Mechanistically, FABP5 may drive tumor progression through PPARβ/δ signaling, epithelial-mesenchymal transition induction, angiogenesis regulation, and potential effects on fatty acid metabolism and hypoxia-related pathways.
FABP5 overexpression correlates with adverse clinicopathological features and prognosis in digestive system malignancies, suggesting its potential as a biomarker for these tumors. Further research is warranted.
消化系统恶性肿瘤是全球主要的健康负担,脂肪酸结合蛋白5(FABP5)在这些肿瘤中的作用仍存在争议。
本荟萃分析旨在评估FABP5表达与消化系统恶性肿瘤的临床病理特征以及生存结局之间的相关性。
分析了从PubMed、Embase、Cochrane图书馆、中国知网和万方检索到的11项研究(1207例患者)的数据。
FABP5过表达与较差的总生存期(OS)、更大的肿瘤大小、UICC晚期、血管侵犯和淋巴结转移风险增加相关。值得注意的是,FABP5过表达在消化道恶性肿瘤亚组中与较差的OS特别相关,在中国患者亚组中与更大的肿瘤大小相关。
细胞实验表明,FABP5过表达增强了肝癌(Huh7)和胃癌(HGC-27)细胞系的增殖、迁移和侵袭,而FABP5敲低则降低了这些作用。从机制上讲,FABP5可能通过PPARβ/δ信号传导、诱导上皮-间质转化、调节血管生成以及对脂肪酸代谢和缺氧相关途径的潜在影响来驱动肿瘤进展。
FABP5过表达与消化系统恶性肿瘤的不良临床病理特征和预后相关,表明其作为这些肿瘤生物标志物的潜力。有必要进行进一步研究。